QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 immunome-q3-eps-065-misses-058-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.58) by...

 immunome-presented-preclinical-data-showing-its-proprietary-antibody-drug-conjugate-payload-hc74-overcomes-multiple-mechanisms-of-adc-resistance-including-payload-efflux-and-target-heterogeneity-at-the-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics

Immunome, Inc. (NASDAQ:IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer th...

 goldman-sachs-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-26

Goldman Sachs analyst Salveen Richter initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Tar...

 craig-hallum-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-26

Craig-Hallum analyst Adam Vogel initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of...

 guggenheim-reiterates-buy-on-immunome-maintains-25-price-target

Guggenheim analyst Michael Schmidt reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $25 price target.

 evercore-isi-group-initiates-coverage-on-immunome-with-outperform-rating-announces-price-target-of-18

Evercore ISI Group analyst Cory Kasimov initiates coverage on Immunome (NASDAQ:IMNM) with a Outperform rating and announces ...

 jp-morgan-maintains-overweight-on-immunome-lowers-price-target-to-22

JP Morgan analyst Brian Cheng maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $23 to $22.

 immunome-q1-eps-052-beats-068-estimate-sales-293m-beat-28571k-estimate

Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.68) by 2...

 lake-street-initiates-coverage-on-immunome-with-buy-rating-announces-price-target-of-23

Lake Street analyst Chad Messer initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of...

 wedbush-reiterates-outperform-on-immunome-maintains-33-price-target

Wedbush analyst David Nierengarten reiterates Immunome (NASDAQ:IMNM) with a Outperform and maintains $33 price target.

 stephens--co-reiterates-overweight-on-immunome-maintains-30-price-target

Stephens & Co. analyst Sudan Loganathan reiterates Immunome (NASDAQ:IMNM) with a Overweight and maintains $30 price target.

 guggenheim-maintains-buy-on-immunome-lowers-price-target-to-25

Guggenheim analyst Michael Schmidt maintains Immunome (NASDAQ:IMNM) with a Buy and lowers the price target from $35 to $25.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION